Business
Jaguar Health Enters Deal with Atlas Sciences to Develop NP-500, a Jaguar Non-Core Plant-based Type II Diabetes Drug Candidate
Jaguar concurrently receives $1.5 million and exclusive 10-year license from purchaser to develop and commercialize NP-500 through sale of NP-500 technology
About this update from Jaguar Health, Inc.
[{"type":"text","content":"Jaguar concurrently receives $1.5 million and exclusive 10-year license from purchaser to develop and commercialize NP-500 through sale of NP-500 technology and IPDeal brings in immediate non-dilutive capital to fund pipeline of plant-based prescription drug candidates of Jaguar's Napo Pharmaceuticals subsidiarySAN FRANCISCO, CA / ACCESSWIRE / April 16, 2020 / Jaguar Health, Inc. (NASDAQ:JAGX) today announced it has entered into an agreement with Atlas Sciences, LLC to develop NP-500, a non-core Jaguar plant-based type II diabetes drug candidate which has successfully completed Phase 1 clinical trials. The deal involves the receipt of $1.5 million by Napo Pharmaceuticals, Inc. (Napo), Jaguar's wholly-owned subsidiary, for sale of NP-500's technology and intellectual property to Atlas Sciences. Concurrently with this sale, Jaguar received an exclusive 10-year license to develop and commercialize NP-500 technology in all territories worldwide except greater China, inclusive of the right to sublicense NP-500 development and commercialization rights.\"We are pleased to enter into this agreement with Atlas Sciences, as it supports our strategy to bring in non-dilutive capital to fund Napo's plant-based R&D pipeline,\" said Lisa Conte, Jaguar's president and CEO. \"While we remain laser-focused on maximizing the full potential of our non-opioid prescription product Mytesi® (crofelemer) - which is unrelated to NP-500 and is the only oral plant-based medicine approved by the FDA under botanical guidance - we look forward to potentially forging additional non-dilutive funding partnerships to advance key potential pipeline indications into development, commercialization, and access outside the U.S.\"NP-500 is a plant-based drug product candidate for treatment of type II diabetes and insulin-resistance syndrome in humans. Derived from a plant found in North America, NP-500 is a hormone-sensitive lipase inhibitor that has already completed Phase 1 safety testing in humans and substantial pre-clinical animal testing for type II diabetes. Its novel mechanism of action has been shown in animal models to increase insulin sensitivity, reduce blood glucose levels, reduce serum free fatty acids and triglycerides, and provide a potential benefit for blood pressure. In traditional medicine, the plant was brewed as a tea and used for the treatment of...